All articles by  

  1. FDA approves Nucala to treat severe eosinophilic asthma in children

    GlaxoSmithKline (GSK) has received the approval of the US Food and Drug Administration (FDA) for its Nucala (mepolizumab) drug to…
    Read More…

    13 Sep
  2. Inotrem secures funds to develop septic shock treatment

    Biotechnology company Inotrem has secured series B funding to develop immunotherapy candidates targeting septic shock and chronic inflammatory conditions. The…
    Read More…

    13 Sep
  3. Penn researchers study cancer therapy in heart disease treatment

    A research team from Penn Medicine at the University of Pennsylvania has been studying CAR T-cell therapy, which is used…
    Read More…

    13 Sep
  4. Atomwise inks four new deals for AI-based drug discovery

    US-based Atomwise has formed four new alliances to leverage its artificial intelligence (AI) technology for the discovery of new drugs…
    Read More…

    12 Sep
  5. UK initiates £200m genome project to address fatal diseases

    The UK Government has launched a £200m whole-genome sequencing project in alliance with pharmaceutical companies and health experts to tackle…
    Read More…

    12 Sep
  6. GSK to buy Sitari Pharmaceuticals from Avalon Ventures

    UK-based pharmaceutical company GlaxoSmithKline (GSK) has signed a definitive agreement with Avalon Ventures to acquire Sitari Pharmaceuticals for an undisclosed…
    Read More…

    11 Sep
  7. Sanofi to pay Lexicon $260m over terminated Zynquista alliance

    Lexicon Pharmaceuticals has announced a $260m settlement with Sanofi over the termination of their alliance, which focused on the development…
    Read More…

    11 Sep
  8. FDA approves Boehringer’s Ofev for rare lung disease

    The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Ofev (nintedanib) medicine to slow the rate of pulmonary…
    Read More…

    10 Sep
  9. Flexion Therapeutics licences pain therapy from Xenon

    US-based Flexion Therapeutics has signed an agreement with Canadian Xenon Pharmaceuticals to acquire worldwide rights for the development and commercialisation…
    Read More…

    10 Sep
  10. Genmab partners Tempus to identify new cancer targets

    Danish biotechnology company Genmab has partnered with US-based technology firm Tempus to research and develop disease targets in oncology. Tempus…
    Read More…

    10 Sep
Close
Close
Close